Novartis RNA Therapy Shows Promise in Treating Rare Muscular Dystrophy

For people living with facioscapulohumeral muscular dystrophy (FSHD), daily life can be a struggle. FSHD is a rare genetic disorder that causes progressive muscle weakness, often leading to mobility issues and the need for wheelchairs. However, recent clinical trial results from Novartis have brought new hope to patients and their families.

Novartis's experimental RNA therapy, delpacibart braxlosiran (del-brax), has demonstrated promising outcomes in a Phase 1/2 study named FORTITUDE. The therapy is designed to reduce the expression of DUX4 messenger RNA, which plays a crucial role in the muscle damage associated with FSHD. By targeting this specific genetic mechanism, del-brax aims to slow or even halt the progression of the disease.

In the FORTITUDE trial, Novartis reported that del-brax led to significant reductions in blood levels of cDUX, a biomarker of FSHD. This achievement meets the primary goal of the biomarker cohort in the placebo-controlled study. The therapy showed a reduction in creatine kinase, another protein that indicates muscle damage, further supporting its potential effectiveness.

A New Class of RNA Therapies

Del-brax is part of an emerging class of treatments known as antibody oligonucleotide conjugates (AOCs). These therapies combine the targeting precision of antibodies with the therapeutic power of oligonucleotides to modify RNA function. In the case of del-brax, the antibody delivers an oligonucleotide that specifically targets and reduces DUX4 mRNA expression.

The development of AOCs represents a significant advancement in genetic medicine, offering new possibilities for treating conditions previously considered untreatable. Novartis's acquisition of Avidity Biosciences, the original developer of del-brax, for $12 billion underscores the company's commitment to this innovative approach.

Avidity had already reported promising Phase 1/2 results showing that del-brax not only reduced DUX4 expression but also showed signs of improving muscle function. These findings laid the groundwork for a larger, placebo-controlled Phase 3 clinical trial, which began last year. This trial will serve as the confirmatory study if del-brax receives accelerated approval from regulatory bodies.

What Comes Next

The next steps for del-brax include further analysis of the FORTITUDE trial data and preparation for potential regulatory submissions. Avidity's previous agreement with the FDA that cDUX reduction can serve as a surrogate endpoint for accelerated approval could expedite the process, bringing hope to patients who have few treatment options.

If approved, del-brax would be the first targeted therapy for FSHD, marking a significant milestone in the treatment of this rare disorder. The potential impact on public health is substantial, as it could improve the quality of life for thousands of individuals and their families.

The broader implications extend beyond FSHD. The success of AOCs like del-brax could open new avenues for treating other genetic disorders, further advancing the field of RNA medicine. As research continues, the potential to address a wide range of conditions with precision and efficacy becomes increasingly promising.

For now, the focus remains on ensuring that del-brax meets all safety and efficacy standards in ongoing trials. The journey from lab to patient is long and complex, but the progress made so far offers a beacon of hope for those affected by FSHD and other rare genetic diseases.